Drug intelligence / Profile preview

VN-0103

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

**VN-0103** is an investigational adsorbed acellular pertussis-diphtheria-tetanus combination vaccine developed by Daiichi Sankyo for active booster immunization against pertussis, diphtheria, and tetanus. The vaccine contains purified pertussis antigens together with diphtheria and tetanus toxoids and is intended to induce protective humoral immune responses against these antigens. A randomized, observer-blind Phase 3 study evaluated a single 0.5 mL subcutaneous dose in Japanese adolescents aged 11–12 years, using diphtheria-tetanus toxoid as the active comparator. ([jrct.mhlw.go.jp](https://jrct.mhlw.go.jp/en-latest-detail/jRCT2080222484))

Other names: Adsorbed purified pertussis-diphtheria-tetanus combined vaccineVN 0103VN0103VN-0103

Targets

Diphtheria toxinFHA (Filamentous hemagglutinin)

Beyond the preview

Go deeper on VN-0103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VN-0103.

Explore the full profile